These engineered T cells co-express an EGFRvIII-specific CAR with an EGFR-specific BiTE, thus combining high tumor specificity (conferred by the EGFRvIII-CAR) with complete tumor eradication (mediated by the EGFR-BiTE locally secreted in the tumor).21 This evidence concerns the gene EGFR and neoplasm.